Cargando…
Enhancement of chemotherapy and nitroimidazole-induced chemopotentiation by the vasoactive agent hydralazine.
Nitroimidazoles have been shown to be potent sensitisers of certain clinically active chemotherapeutic agents. This process of chemopotentiation has been shown to be hypoxia-mediated. The present studies evaluated whether increasing the level of hypoxia in the tumour tissue, by treatment with the va...
Autor principal: | Siemann, D. W. |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
1990
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1971466/ https://www.ncbi.nlm.nih.gov/pubmed/2206941 |
Ejemplares similares
-
Chemopotentiation in vivo: no loss of sensitization with fractionation.
por: Hill, S. A., et al.
Publicado: (1984) -
Hypoxic cells and in situ chemopotentiation of the nitrosoureas by misonidazole.
por: Wheeler, K. T., et al.
Publicado: (1984) -
Potentiation of the anti-tumour effect of melphalan by the vasoactive agent, hydralazine.
por: Stratford, I. J., et al.
Publicado: (1988) -
Chemopotentiation of CCNU metabolites by misonidazole.
por: Mulcahy, R. T.
Publicado: (1985) -
Proceedings of the Workshop on the Enhancement of Chemotherapy by Nitroimidazoles
Publicado: (1982)